1. Home
  2. AURE vs IMUX Comparison

AURE vs IMUX Comparison

Compare AURE & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AURE

Prestige Wealth Inc. Class A Ordinary Shares

N/A

Current Price

$2.28

Market Cap

86.5M

Sector

Finance

ML Signal

N/A

Logo Immunic Inc.

IMUX

Immunic Inc.

N/A

Current Price

$1.33

Market Cap

75.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AURE
IMUX
Founded
2018
2016
Country
Hong Kong
United States
Employees
N/A
66
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
86.5M
75.2M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
AURE
IMUX
Price
$2.28
$1.33
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$4.25
AVG Volume (30 Days)
215.4K
4.7M
Earning Date
01-01-0001
05-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.51
52 Week High
$3.53
$1.38

Technical Indicators

Market Signals
Indicator
AURE
IMUX
Relative Strength Index (RSI) 66.97 75.59
Support Level $0.29 $0.61
Resistance Level $3.53 N/A
Average True Range (ATR) 0.40 0.11
MACD 0.05 0.03
Stochastic Oscillator 38.43 89.72

Price Performance

Historical Comparison
AURE
IMUX

About AURE Prestige Wealth Inc. Class A Ordinary Shares

Aurelion Inc is engaged in providing private wealth management and asset management services to high-net-worth and ultra-high-net-worth individuals by identifying and purchasing well-matched wealth management products offered by third-party providers. Its subsidiary operates a wealth management business that works with licensed product brokers in Hong Kong, currently consisting solely of insurance brokers distributing insurance products, and assists in customizing wealth management investment portfolios for clients. The Company generates revenue for its subsidiaries' wealth management business from product brokers in the form of referral fees, which are calculated based on the value of wealth management products purchased by clients from such brokers.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: